LONG-TERM OUTCOMES OF RITUXIMAB THERAPY IN PATIENTS WITH NONINFECTIOUS POSTERIOR UVEITIS REFRACTORY TO CONVENTIONAL IMMUNOSUPPRESSIVE THERAPY

Autor: Manuel Valdes Navarro, Caiyun You, C. Stephen Foster, Andres F. Lasave, khawla abusamra, Lina Ma, Neerav Lamba, Halea Meese
Rok vydání: 2018
Předmět:
Adult
Male
medicine.medical_specialty
Time Factors
Visual acuity
Adolescent
Fundus Oculi
medicine.medical_treatment
Optic Disk
Drug Resistance
Visual Acuity
Optic disk
Young Adult
03 medical and health sciences
0302 clinical medicine
Refractory
medicine
Humans
Fluorescein Angiography
Aged
Retrospective Studies
Aged
80 and over
Immunosuppression Therapy
030203 arthritis & rheumatology
medicine.diagnostic_test
business.industry
Uveitis
Posterior
Immunosuppression
General Medicine
Middle Aged
medicine.disease
Fluorescein angiography
Surgery
Posterior segment of eyeball
Ophthalmology
Treatment Outcome
Antirheumatic Agents
Injections
Intravenous
030221 ophthalmology & optometry
Female
Rituximab
medicine.symptom
business
Immunosuppressive Agents
Tomography
Optical Coherence
Uveitis
Follow-Up Studies
medicine.drug
Zdroj: Retina. 38:395-402
ISSN: 0275-004X
Popis: Purpose To assess long-term effectiveness of rituximab therapy for refractory noninfectious uveitis affecting the posterior segment. Methods Retrospective case series. Patients diagnosed with recalcitrant noninfectious posterior uveitis who were treated with rituximab intravenous infusions between 2010 and 2015 were included. Patients underwent best-corrected visual acuity testing and fluorescein angiography evidence of disk or vascular staining at 6, 12, 18, and 24 months. Patients had at least 24 months of follow-up. Results Eleven patients (21 eyes) with refractory posterior uveitis treated with intravenous rituximab were included. Nine (81.8%) patients were female. Mean follow-up was 29.3 ± 7.8 months. rituximab was administered as complementary therapy because of previous inefficacy of other therapies in 7 (63.7%) patients, and it was the only treatment in four (36.3%) patients who did not tolerate other drugs. Inflammation signs by fluorescein angiography were controlled in nine (81.8%) patients at the end of follow-up. Baseline best-corrected visual acuity was 20/80 (logarithm of the minimal angle of resolution 0.6 ± 0.4), and final best-corrected visual acuity was 20/40 (0.3 ± 0.5) (P = 0.005). No significant side effects were reported. Conclusion Rituximab therapy was associated with stability and remission of recalcitrant noninfectious posterior uveitis in patients who did not tolerate or did not respond to other therapies.
Databáze: OpenAIRE
Externí odkaz: